Shopping Cart
Remove All
Your shopping cart is currently empty
PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor with an IC50 of 785.6 nM, demonstrating antitumor activity in vivo.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor with an IC50 of 785.6 nM, demonstrating antitumor activity in vivo. |
| In vitro | PD-L1-IN-5 (X22) exhibits no significant cytotoxic effects in vitro on MC38 and CT26 cells at concentrations ranging from 0 to 150 μM over a 12-hour period. |
| In vivo | PD-L1-IN-5 (X22), administered orally at doses of 5 or 25 mg/kg daily for 20 consecutive days, demonstrates significant antitumor activity through partial toxicity upregulation of tumor-infiltrating CD8+ T cells in mouse models of MC38 and CT26 colon cancer. However, it shows reduced antitumor effects in immunodeficient nude mice with syngeneic CT26 colorectal cancer, indicating its mechanism relies on the immune system. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.